Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer.
Journal: JCO oncology practice
Published: November 03, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.
Journal: Investigational new drugs
Published: August 11, 2025
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort.
Journal: European urology
Published: April 22, 2025
Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer.
Journal: The Prostate
Published: June 29, 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 05, 2023
Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 27, 2014
Showing 1-6 of 6
Last Updated: 09/26/2026